MedCity News July 27, 2021
Blending computational biology and AI-based methods, the goal is to identify new targets, pair these with effective chemistry, and define biomarkers to optimally position novel therapies.
Precision medicine today is predicated on the potential for biomarkers to ensure the success of today’s most promising drugs by stratifying patient cohorts and guiding indication selection. Less appreciated is the utility of biomarkers to contribute to the discovery of tomorrow’s next generation therapeutics. Ideally, a biomarker discovery platform is designed to serve as an end-to-end solution that not only de-risks clinical development, but also drives early discovery and supports translational investigations. Linking these different stages in the drug R&D lifecycle can be transformational, creating important feedback of data and information.
Biomarker-driven drug development...
Today's Sponsors
Today's Sponsor